Novo Nordisk Slashes Ozempic, Wegovy List Prices Up To 50% Starting 2027
Novo Nordisk announced it will reduce list prices of Wegovy, Ozempic, and Rybelsus by 35% to 50% to $675 monthly starting in 2027, aiming to regain market share from rival Eli Lilly and improve access for high-deductible patients.
Battling to regain its market share over rival Eli Lilly, Novo Nordisk announced Tuesday that it will reduce the list prices of its popular weight loss drug Wegovy and diabetes drugs Ozempic and Rybelsus by up to half starting in 2027. The company will cut 35% to 50% off the list price of its semaglutide products to $675 a month.
Lowering the list price makes GLP-1 drugs more accessible for patients, including those who have high deductibles and those who pay coinsurance for medications. For insured patients who have to pay coinsurance — a certain percentage of the list price — when buying prescription drugs, or for those in high-deductible plans who need to pay list prices before meeting deductibles, the move will bring down out-of-pocket costs.
However, in the complicated world of drug pricing, the price cut may not mean many more payers will cover the drugs, which would allow more people to get them. What matters to employers and other payers when making coverage decisions are net prices — the actual prices they pay after rebates and discounts.
In related developments, Brazil's top court refused to extend the semaglutide patent, reinforcing that no patent term adjustments are judicially available and demanding other strategies from life sciences companies. The decision establishes a hard 20-year patent term cap for pharmaceutical products in Brazil.